Literature DB >> 8951060

A proteoglycan that activates fibroblast growth factors during early neuronal development is a perlecan variant.

S J Joseph1, M D Ford, C Barth, S Portbury, P F Bartlett, V Nurcombe, U Greferath.   

Abstract

Cells in the early embryonic vertebrate nervous system are dependent on members of the fibroblast growth factor (FGF) family for their proliferation and subsequent differentiation. These growth factors will only bind to their specific high affinity cell surface receptors after formation of a ternary complex with the glycosaminoglycan heparan sulfate. Such specific heparan sulfates are secreted as proteoglycans from neural precursor cells and localise to their surfaces. One such proteoglycan, HSPG-PRM (Perlecan-related molecule), was isolated through its ability to potentiate neural cell responses to either FGF-1 or FGF-2. In this study, we have verified the relative molecular mass of the core protein of PRM as 45,000 and obtained partial amino acid sequence from it. The sequences bore significant homology to native perlecan. A probe generated by reverse transcriptase polymerase chain reaction using oligonucleotides designed from the protein sequence used on northern blots of RNA from a neuroepithelial cell line detected perlecan at 12.6 kilobases, as well as novel transcripts at 6.5 and 3.5 kilobases. The latter species appears by virtue of its size and abundance to be the novel PRM transcript. PRM appears to be encoded by the same gene as perlecan, as genomic Southern blotting only detected a single gene. Polyclonal antibodies raised against the PRM molecule detected a single proteoglycan species at 290x10(3) with a core protein of 45x10(3). Polyclonal anti-perlecan antibodies cross-reacted with PRM confirming their relatedness, although immunohistochemical studies revealed a differential staining pattern for PRM as compared to perlecan within the developing nervous system. The PRM molecule was shown to be localised to several different tissues of the developing embryo, indicating that it plays a broad role. We conclude that PRM is a variant of perlecan that is differentially glycosylated in a manner that confers highly specific functions at critical stages of neural development and tissue growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8951060     DOI: 10.1242/dev.122.11.3443

Source DB:  PubMed          Journal:  Development        ISSN: 0950-1991            Impact factor:   6.868


  9 in total

1.  The role of cells, neurotrophins, extracellular matrix and cell surface molecules in peripheral nerve regeneration.

Authors:  Murali Naidu
Journal:  Malays J Med Sci       Date:  2009-04

2.  Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: a role in angiogenesis and wound healing.

Authors:  Moonsun Jung; Megan S Lord; Bill Cheng; J Guy Lyons; Hatem Alkhouri; J Margaret Hughes; Simon J McCarthy; Renato V Iozzo; John M Whitelock
Journal:  J Biol Chem       Date:  2012-12-12       Impact factor: 5.157

3.  Phenotypic alterations in Kaposi's sarcoma cells by antisense reduction of perlecan.

Authors:  C Marchisone; F Del Grosso; L Masiello; M Prat; L Santi; D M Noonan
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

4.  Epidermal transformation leads to increased perlecan synthesis with heparin-binding-growth-factor affinity.

Authors:  P Tapanadechopone; S Tumova; X Jiang; J R Couchman
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

5.  Dynamic expression patterns of ECM molecules in the developing mouse olfactory pathway.

Authors:  Elaine L Shay; Charles A Greer; Helen B Treloar
Journal:  Dev Dyn       Date:  2008-07       Impact factor: 3.780

6.  Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1.

Authors:  Nundehui Díaz-Lezama; Zhijian Wu; Elva Adán-Castro; Edith Arnold; Miguel Vázquez-Membrillo; David Arredondo-Zamarripa; Maria G Ledesma-Colunga; Bibiana Moreno-Carranza; Gonzalo Martinez de la Escalera; Peter Colosi; Carmen Clapp
Journal:  Lab Invest       Date:  2015-11-16       Impact factor: 5.662

7.  Perlecan and synaptophysin changes in denervated skeletal muscle.

Authors:  Kai Ma; Zhifeng Huang; Jianfeng Ma; Longquan Shao; Huiming Wang; Yanliang Wang
Journal:  Neural Regen Res       Date:  2012-06-15       Impact factor: 5.135

Review 8.  Heparan Sulfate Proteoglycans: Key Mediators of Stem Cell Function.

Authors:  Maanasa Ravikumar; Raymond Alexander Alfred Smith; Victor Nurcombe; Simon M Cool
Journal:  Front Cell Dev Biol       Date:  2020-11-19

9.  A novel use of TAT-EGFP to validate techniques to alter osteosarcoma cell surface glycosaminoglycan expression.

Authors:  Arjuna Kumarasuriyar; Christian Dombrowski; David A Rider; Victor Nurcombe; Simon M Cool
Journal:  J Mol Histol       Date:  2007-09-21       Impact factor: 3.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.